STOCK TITAN

Syros Pharmaceuticals, Inc. - SYRS STOCK NEWS

Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.

Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.

At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.

While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.

Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.

Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.

Rhea-AI Summary
Syros Pharmaceuticals (SYRS) reports financial results and corporate update, on track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 and complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023 with pivotal CR data expected in 3Q 2024. Second Quarter 2023 financial results show a net loss of $36.3 million, cash and financial guidance into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences earnings
Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ:SYRS) has granted a restricted stock unit (RSU) award of 9,000 shares of Syros common stock to a newly hired employee. The RSU was granted as a material inducement to employment and will vest over a period of four years, subject to the employee's continued service with Syros.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
conferences earnings

FAQ

What is the current stock price of Syros Pharmaceuticals (SYRS)?

The current stock price of Syros Pharmaceuticals (SYRS) is $0.292439 as of November 22, 2024.

What is the market cap of Syros Pharmaceuticals (SYRS)?

The market cap of Syros Pharmaceuticals (SYRS) is approximately 7.8M.

What does Syros Pharmaceuticals specialize in?

Syros Pharmaceuticals specializes in mapping gene regulatory circuits and modulating factors that control gene expression to treat diseases.

What is unique about Syros Pharmaceuticals' approach?

Syros utilizes a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to decode gene regulation for therapeutic development.

In which therapeutic areas has Syros Pharmaceuticals shown success?

Syros has demonstrated success primarily in oncology, addressing unmet medical needs in hematologic malignancies.

What recent achievements has Syros Pharmaceuticals made?

Syros has continued to advance its clinical pipeline and establish strategic partnerships to drive innovation in gene control research.

What is the financial condition of Syros Pharmaceuticals?

Syros is well-funded and strategically positioned to continue its extensive research and development efforts in precision medicine.

What is the proprietary platform of Syros Pharmaceuticals?

It is a combination of assay technologies, bioinformatics, and biological insights developed to understand and modulate gene regulation.

How does Syros Pharmaceuticals impact patient treatment?

Syros develops new standards of care for frontline treatment, particularly for patients with hematologic malignancies, aiming to improve patient outcomes.

Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?

Syros is making its mark by leveraging its gene control research to develop innovative therapies, especially in oncology.

Who are the key contributors to Syros Pharmaceuticals' proprietary platform?

The platform has been developed by the experienced senior leadership team at Syros, integrating their expertise in disease biology and genomics.

What is the mission of Syros Pharmaceuticals?

The mission of Syros Pharmaceuticals is to transform the treatment of diseases by harnessing the power of gene control research to develop innovative therapies.

Syros Pharmaceuticals, Inc.

Nasdaq:SYRS

SYRS Rankings

SYRS Stock Data

7.82M
26.18M
2.34%
75.52%
4.65%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE